Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancerChristopher G. Willett, Yves Boucher, Emmanuelle di Tomaso et al.|Nature Medicine|2004Cited by 2k
Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?Rakesh R. Ramjiawan, Dan G. Duda|Angiogenesis|2017Cited by 690
Efficacy, Safety, and Biomarkers of Neoadjuvant Bevacizumab, Radiation Therapy, and Fluorouracil in Rectal Cancer: A Multidisciplinary Phase II StudyChristopher G. Willett, Dan G. Duda, Emmanuelle di Tomaso et al.|Journal of Clinical Oncology|2009Cited by 507
CXCR4 inhibition in tumor microenvironment facilitates anti‐programmed death receptor‐1 immunotherapy in sorafenib‐treated hepatocellular carcinoma in miceYunching Chen, Dan G. Duda|Hepatology|2014Cited by 456
Surrogate Markers for Antiangiogenic Therapy and Dose-Limiting Toxicities for Bevacizumab With Radiation and Chemotherapy: Continued Experience of a Phase I Trial in Rectal Cancer PatientsChristopher G. Willett, Gregory Y. Lauwers, Yves Boucher et al.|Journal of Clinical Oncology|2005Cited by 419